The Parkinson's disease kinase LRRK2 impairs release sites of vulnerable dopamine axons-striatal synaptosomes phosphoproteomic study

We and others previously reported that knock-in mice expressing the pathogenic hyperactive Lrrk2G2019S mutation, exhibit deficits in dopamine release within the striatum. To investigate the underlying molecular mechanisms, we conducted quantitative phosphoproteomic Liquid Chromatography-Mass Spectrometry (LC-MS) studies on striatal synaptosomes from Lrrk2G2019S mice. Mice were treated with vehicle and LRRK2 inhibitor Mli2.